Comparison of efficacy of Indomethacin vs Paracetamol along with standard care of treatment in mild and moderate Covid-19 patients

INTERVENTION: Intervention1: Indomethacin: Drug dose ‐ Capsule (C) ‐ 75 mg sustained release formulation once daily for 5 days for subjects with BMI less than 30; C. 75 mg twice daily for 5 days for subjects with BMI more than 30 will be administered orally, along with standard care of treatment that includes the following C. Doxycycline â?? 100 mg bd; Tablet (T). Ivermectin â?? 12 mg once daily (OD); T. vitamin C 500 mg and D3 60k IU weekly once; T. Zinc 50 mg OD; Cough syrup SOS; T. Cetrizine 10 mg OD /T. Ketotifen 1mg bd SOS; T. Pantoperazole 40 mg bd Control Intervention1: Paracetamol: Tablet ‐ paracetamol 650 mg 4 times daily for 5 days along with same standard care of treatment mentioned for the intervention drug will be administered orally. CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J99‐ Respiratory disorders in diseasesclassified elsewhere PRIMARY OUTCOME: Reduction in Covid‐19 symptoms and the intervention is expected to be beneficial in reducing the Covid 19 symptoms than the comparatorTimepoint: Day 0 screening ; Day 1 to 5 drug administration ; Day 7 end of study SECONDARY OUTCOME: Safety both the intervention and comparator are routinely used drugs and are expected to be safe with no adverse effectsTimepoint: Day 0 screening ; Day 1 to 5 drug administration ; Day 7 end of study INCLUSION CRITERIA: Age between 20 to 90 years RT â?? PCR Positive Hospitalised patients The case criteria for the study â?? Renal Function Test and Liver Functional Test should be normal at the screening; Oxygen saturation should be 95% or more